Publication Name	World Journal of Diabetes
Manuscript ID	58060
Country	Greece

Received	2020-07-05 06:24
Peer-Review Started	2020-07-05 06:24
To Make the First Decision
Return for Revision	2020-07-30 18:01
Revised	2020-08-02 19:51
Second Decision	2020-09-03 10:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2020-09-03 16:16
Articles in Press	2020-09-03 16:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-09-07 00:28
Publish the Manuscript Online	2020-09-11 07:11

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
Manuscript Source	Invited Manuscript
All Author List	Stavroula Veneti and Konstantinos Tziomalos
ORCID	Author(s) ORCID Number Stavroula Veneti http://orcid.org/0000-0002-4970-6982 Konstantinos Tziomalos http://orcid.org/0000-0002-3172-1594
Funding Agency and Grant Number
Corresponding Author	Konstantinos Tziomalos, MD, MSc, PhD, Associate Professor, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi Street, Thessaloniki 54636, Greece. ktziomalos@yahoo.com
Key Words	Diabetic nephropathy; Type 2 diabetes mellitus; Glucagon-like peptide-1 receptor agonists; Liraglutide; Dulaglutide; Semaglutide
Core Tip	Glucagon-like peptide-1 receptor agonists prevent the development of persistent macroalbuminuria in patients with type 2 diabetes mellitus. However, it is unclear whether they delay the decline in glomerular filtration rate in this population. Long-term trials are needed to clarify the role of these agents in the management of diabetic nephropathy.
Publish Date	2020-09-11 07:11
Citation	Veneti S, Tziomalos K. Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy? World J Diabetes 2020; 11(9): 370-373
URL	https://www.wjgnet.com/1948-9358/full/v11/i9/370.htm
DOI	https://dx.doi.org/10.4239/wjd.v11.i9.370

Full Article (PDF)	WJD-11-370.pdf
Full Article (Word)	WJD-11-370.docx
Manuscript File	58060-Review.docx
Answering Reviewers	58060-Answering reviewers.pdf
Audio Core Tip	58060-Audio core tip.wma
Conflict-of-Interest Disclosure Form	58060-Conflict-of-interest statement.pdf
Copyright License Agreement	58060-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	58060-Language certificate.pdf
Peer-review Report	58060-Peer-review(s).pdf
Scientific Misconduct Check	58060-Scientific misconduct check.pdf
Scientific Editor Work List	58060-Scientific editor work list.pdf
CrossCheck Report	58060-CrossCheck report.pdf